Synovial Transcriptome Profiling for Predicting Biological Treatment Response in Rheumatoid Arthritis: A Feasibility study
Rattachement africain : nl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ABSTRACT Introduction Disease-Modifying Anti-Rheumatic Drug (DMARD) treatment fails to achieve clinical remission in a substantial proportion of patients with rheumatoid arthritis (RA). Patient-derived synovial tissue (ST)-signatures, thought to determine this heterogeneity of treatment responses, can be studied by single-cell RNA sequencing (scRNA-seq). Study aims The first aim was to obtain viable ST from RA patients using wrist arthroscopy. The second aim was to identify patient-specific transcriptome signatures from the ST omics data that relate to clinical course and treatment responses in RA. Methods Radiocarpal and midcarpal synovectomy was performed using a standard set-up wrist arthroscopy. Single-cell suspensions of ST from affected wrists of two RA patients and a control subject were processed on the 10X Genomics Chromium Platform. Seurat was used for downstream analysis. Results In two RA patients and one non-inflammatory control, ST was successfully removed during wrist arthroscopy. No surgical complications occurred. For the RA patients and control, 17,176 and 7,884 high-quality cells were analyzed, respectively. Apart from enrichment of cell compartments in RA, including those of B- and plasma cells, T cell populations, NK cells, and macrophages, we observed interpatient variability that may influence the relationship between RA synovial signature and clinical phenotype, potentially also affecting treatment response and outcome. In-depth analysis of the prevailing cell-type abundance phenotype (CTAP) in the RA patients, as described previously, provided insights into the extent to which these CTAPs may be used to predict treatment responses. Conclusion In this feasibility study, we demonstrated that wrist arthroscopy successfully retrieves ST with good tissue viability, which may provide informative and high-quality transcriptomic data for predicting therapy response at an individual level.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Synovial Transcriptome Profiling for Predicting Biological Treatment Response in Rheumatoid Arthritis: A Feasibility study
- Date Crossref
- 29/08/2024
- Éditeur
- openRxiv
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Maasstad Ziekenhuis pays non établi dans la noticeÉtablissement de santé
-
Erasmus MC pays non établi dans la noticeÉtablissement de santé
-
Erasmus University Rotterdam pays non établi dans la noticeUniversité ou école supérieure
-
Amsterdam University Medical Centers pays non établi dans la noticeÉtablissement de santé
-
University of Amsterdam pays non établi dans la noticeUniversité ou école supérieure
-
Maasstad hospital Department of Surgery pays non établi dans la noticeÉtablissement de santé
-
Erasmus Medical Center Rotterdam Department of Obstetrics and Fetal Medicine pays non établi dans la noticeÉtablissement de santé
-
Department of Obstetrics and Fetal Medicine pays non établi dans la noticeInstitution
-
Department of Rheumatology and Clinical immunology pays non établi dans la noticeÉtablissement de santé
-
Amsterdam University Medical Center location AMC pays non établi dans la noticeUniversité ou école supérieure
Maasstad Ziekenhuis, Erasmus MC et Erasmus University Rotterdam, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.